Management of bone and metabolic effects of androgen deprivation therapy
Androgen Deprivation Therapy (ADT) has established roles in the neoadjuvant treatment of high risk localized prostate cancer (CaP) together with radiotherapy, and in biochemically recurrent nonmetastatic, and metastatic disease. Use of gonadotrophin-releasing hormone (GnRH) analogs as a means of blocking testosterone production is currently the most commonly used ADT modality. As long-term survival in men receiving ADT is the norm, it is appropriate to focus on identification and mitigation of adverse effects of this therapy.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Nicholas Russell, Mathis Grossmann Tags: Seminars Article Source Type: research
More News: Cancer | Cancer & Oncology | Hormones | Neoadjuvant Therapy | Prostate Cancer | Urology & Nephrology